Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)

RecruitingOBSERVATIONAL

Enrollment

160,000

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions

RSV

Interventions

BIOLOGICAL

Nirsevimab

Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study

Trial Locations (1)

RECRUITING

ISCI, Santiago

All Listed Sponsors

lead

Instituto Sistemas Complejos de Ingeniería

OTHER